Tamoxifen in postmenopausal women: A safety perspective

Drugs and Aging

Volumn 8, Issue 5, 1996, Pages 329-337

  Robinson, Emily ^a   Kimmick, Gretchen G ^a   Muss, Hyman B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; LIPID; TAMOXIFEN;

BONE DENSITY; BONE MINERAL; BREAST CANCER; BREAST METASTASIS; CANCER GRADING; CLINICAL TRIAL; DEATH; DEPRESSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIUM CARCINOMA; EYE TOXICITY; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; LIVER TOXICITY; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VAGINA DISCHARGE;

EID: 0029932612     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608050-00002     Document Type: Review

References (46)

1. Miller AB. Incidence and demographics: radiation risk. In: Harris JR, Hellman S, Henderson IC, et al., editors. Breast diseases. 2nd ed. Philadelphia: Lippincott, 1991: 119-26
2. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. Ca Cancer J Clin 1995; 46 (1): 5-27
3. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-29
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15, 71-85
5. Kimmick G, Muss HB. Current status of endocrine therapy for metastatic breast cancer. Oncology 1995; 9: 877-90
6. Jordan VC. Tamoxiten for breast cancer prevention. Proc Soc Exp Biol Med 1995; 208: 144
7. Tamoxifen. In: Dorr RT, Von Hoff DD, editors. Cancer chemotherapy handbook. Norwalk (CT): Appleton and Lange, 1994: 866-75
8. National Cancer Institute Clinical Announcement. Bethesda: US Department of Health and Human Services, 30 November 1995
9. Spicer D, Pike MC, Henderson BB. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 1990; 4: 49-59
10. Henderson IC. Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, et al., editors. Breast diseases. 2nd ed. New York: Lippincott, 1991: 559-603
11. Love RR, Mazess RB, Tormey DC, et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988; 12: 297-302
12. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852-6
13. Fornander T, Rutqvist LE, Sjöberg HE, et al. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019-24
14. Ingram D. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. Aust NZ J Surg 1990; 60: 673-5
15. Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988; 12: 307-10
16. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4
17. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85: 1398-406
18. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435-7
19. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7 (6): 803-15
20. Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Int Med 1991; 151: 1842-7
21. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-84
22. Cummings FJ, Gray R, Davis TE, et al. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer: a double-blind comparison with placebo. Ann Int Med 1985; 103: 324-9
23. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer: analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985; i: 836-40
24. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 97 (6A): 24S-32S
25. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-94
26. Jones AL, Powles TJ, Treleaven JG, et al. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992; 66: 744-7
27. Love RR, Surawicz, TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Int Med 1992; 152: 317-20
28. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-9
29. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992; 69: 2961-4
30. Blackburn AM, Amiel SA, Millis RR, et al. Tamoxifen and liver damage. BMJ 1984; 289: 288
31. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Int Med 1995; 123: 236
32. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A (11): 1714-21
33. 32P-postlabelling DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16 (7): 1651-4
34. Barakat R. The effect of tamoxifen on the endometrium. Oncology 1995; 9: 129-39
35. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984; 44: 4006-10
36. Gottardis MM, Robinson SP, Satyaswaroop PG, et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812-5
37. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-3
38. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343: 1318-21
39. Gal D, Kopel S, Bashevkin M, et al. Oncologic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Preliminary report. Gynecol Oncol 1991; 42: 120-3
40. Gibson LE, Barakat RR, Curtin JP, et al. Tamoxifen effects on the endometrium: a retrospective comparative study [abstract 837]. Proc Am Soc Clin Oncol 1994; 13: 263
41. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20
42. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86 (7): 527-37
43. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90
44. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994; 55: 164-8
45. Fornander T, Hellstrom A, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 1850-5
46. Fornander T, Rutqvist LE, Wilking N. Effects of tamoxifen on the female genital tract. Ann NY Acad Sci 1991; 622: 469-76